Close

SARS-CoV

SARS-CoV-2 is a novel coronavirus responsible for the 2020 COVID-19 pandemic. The virus was first identified in the respiratory tract of patients with pneumonia in Wuhan, Hubei China, in December 2019 and declared a pandemic by the World Health Organization (WHO) on March 11, 2020.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Filter By:
Clear Results
29 Results
Name
Type
Format
Host/Source
Isotype
Tested Apps
Unit
Catalog
SDS
COA
Request Sample
SARS-CoV-2, S1 Trimer
Antigen, Other
Liquid
-
N/A
N/A
MG
9566
SARS-CoV-2 S1 RBD,b.1.351
Antigen, Other
Purified
-
N/A
N/A
MG
9568
SARS-CoV-2 S1 RBD, L452rMutant
Antigen, Other
Purified
-
N/A
N/A
MG
9598
SARS-CoV-2 S1 RBD B.1.617
Antigen, Other
Liquid
Human
N/A
N/A
MG
9599
SARS-CoV-2s1RBD,b.1.617.2delta
Antigen, Other
Purified, Liquid
Insect Cells
N/A
EIA
MG
9606
MAb to SARS-CoV-2 Nucleocapsid
Monoclonal
Aff.Pur.
Mouse
IgG1
EIA, LF, WB
MG
9547
MAb to SARS-CoV-2 Nucleocapsid
Monoclonal
Aff.Pur.
Mouse
IgG1
EIA, LF, WB
MG
9548
MAb to SARS-CoV-2 Nucleocapsid
Monoclonal
Purified
Cell Culture
IgG1
EIA, LF, WB
MG
9549
SARS-CoV-2 Spike S1 (RBD)
Antigen, Other
Aff.Pur.
HEK Cells
N/A
EIA, LF, WB
MG
9552
SARS-CoV-2 Np (dykddddk-tag)
Antigen, Other
Aff.Pur.
HEK Cells
N/A
EIA, LF, WB
MG
9554
SARS-CoV-2 Spike S1 (ntd)
Antigen, Other
Aff.Pur.
Insect Cells
N/A
EIA, WB
MG
9557
SARS-CoV-2 Spike S1 (RBD)
Antigen, Other
Aff.Pur.
Insect Cells
N/A
EIA, WB
MG
9558
SARS-CoV-2 Spike S2 (his-tag)
Antigen, Other
Aff.Pur.
Insect Cells
N/A
EIA, WB
MG
9559
SARS-CoV-2 Np (his-tag)
Antigen, Other
Aff.Pur.
Insect Cells
N/A
EIA, WB
MG
9560
SARS-CoV-2 Spike S1 (his-tag)
Antigen, Other
Aff.Pur.
Insect Cells
N/A
EIA, WB
MG
9556
MAb to SARS-CoV-2 S1, Trimeric
Monoclonal
Purified
Cell Culture
IgG1
EIA, LF, Pr, WB
MG
9550
MAb to SARS-CoV-2 S1, Trimeric
Monoclonal
Purified
Cell Culture
IgG2b
EIA, LF, Pr, WB
MG
9551
MAb to SARS-CoV-2, Trimeric S1
Monoclonal
Purified
Cell Culture
IgG1
EIA, LF, Pr, WB
MG
9565
MAb to SARS-CoV-2 Nucleocapsid
Monoclonal
Purified, Liquid
Human Plasma
IgG1
EIA
MG
9572
SARS-CoV-2 S1 RBD, P.1 Mutant
Antigen, Other
Purified
-
N/A
EIA, WB
MG
9569
SARS-CoV-2 S1 RBD, Uk B.1.1.7
Antigen, Other
Purified
-
N/A
EIA, WB
MG
9567
SARS-CoV, E Protein, Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18520
SARS-CoV, Spike (middle) Recom
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18526
SARS-CoV, Spike (c-term) Recom
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18572
SARS-CoV, Nucl.(340-390) Recom
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18402
Rabbit A' SARS-CoV, Spike (nt)
Polyclonal
Aff.Pur.
Rabbit
N/A
EIA
MG
B88139R
Rabbit A' SARS-CoV, Spike (ct)
Polyclonal
Aff.Pur.
Rabbit
N/A
EIA
MG
B88502R
SARS-CoV, Nucl. (1-49) Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18325
SARS-CoV, Spike (n-term) Recom
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18850

SARS-CoV-2

SARS-CoV-2 is an enveloped RNA virus that has four main structural proteins including spike (S) glycoprotein, small envelope (E) glycoprotein, membrane (M) glycoprotein, and the nucleocapsid (N) protein. The spike or S glycoprotein is a transmembrane protein that forms homotrimers which protrude from the viral surface and facilitate the binding of envelope viruses to host cells via ACE2-receptors. The nucleocapsid (N protein) is the structural component of the virus necessary for viral RNA transcription and replication. The membrane or M protein plays a role in determining the shape of the virus envelope, helps to stabilize nucleocapsids and promotes the completion of viral assembly. The envelope or E protein is the smallest protein in the SARS-CoV-2 structure, and it plays a role in the production and maturation of this virus.

The pathogenesis of SARS-CoV-2 infection in humans manifests itself as mild symptoms to severe respiratory failure. Elderly patients and those with serious pre-existing diseases (e.g. hypertension, diabetes, obesity, and cardiovascular disease) tend to have more severe outcomes and the highest death rate. The main cause of death is from respiratory failure due to acute respiratory distress syndrome (ARDS) brought on by a rapid and uncontrolled inflammatory signaling cascade called a “cytokine storm”. The initial trigger for the cytokine storm is not yet known but it likely involves the immune system’s detection of a large quantity of viral antigens released by dying cells.

Diagnosis

Viral tests for COVID-19 that diagnose an acute infection rely on the detection SARS-CoV-2 nucleic acid or antigen using nasopharyngeal swabs. Most antigen detection assays use antibodies that recognize SARS-CoV-2 nucleocapsid protein as it is the most abundant viral protein. Spike protein has also been targeted, especially in assays that use alternative sample types such as saliva or nasal swabs that can be collected by an individual.

Serology tests to determine an individual’s immune status to SARS-CoV-2 use recombinant antigens to detect IgA, IgG or IgM specific antibodies. Tests that detect IgG/IgM to the nucleoprotein are relatively the most sensitive due to the high concentration of nucleoprotein and consequently, antibodies generated against the nucleoprotein. However, the RBD domain of the S-protein is the host attachment protein, and antibodies to RBD are more specific and can be neutralizing. (Sethuraman, N. et al (2020). Interpreting Diagnostic Tests for SARS-CoV-2.AMA. 323(22):2249-2251). To broaden an assay’s coverage and increase its sensitivity and specificity, several diagnostics manufactures use several antigens (e.g. N, S1, RBD) within a single assay.

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

About

Welcome to

Please select your country to continue

Continue
EN